Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Parker Acquires SciLog to Strengthen Single-use System Capability

Published: Friday, August 24, 2012
Last Updated: Thursday, August 23, 2012
Bookmark and Share
Acquisition will allow Parker to deliver an enhanced bioprocessing portfolio.

Parker Hannifin Corporation has announced the acquisition of SciLog Inc, a provider of unique and proprietary single-use technologies and systems for the biopharmaceutical market to support their on-going development as a key supplier to the growing single-use market.

The acquisition will allow Parker to deliver an enhanced bioprocessing portfolio combining filtration and separation expertise, disposable bag systems and automated single-use solutions.

SciLog will be integrated into Parker's Process Filtration Division, which provides high-purity filtration and separation solutions coupled with disposable bags and tubing assemblies for applications such as cell culture media and buffer preparation, product stream filtration and sterile fill finish.

Parker's offering to customers will be enhanced through the addition of SciLog's patented sensor technology for process monitoring and control coupled with unique automation technology from lab to production scale in upstream and downstream processing.

"The addition of SciLog perfectly complements our existing core strengths in filtration and disposable assemblies for the biopharmaceutical market," said Dr Mike Brailsford, General Manager at Parker's Process Filtration Division.

Dr Brailsford continued, "Our customers will now benefit from complete, turnkey solutions that enhance productivity, increase cost-effectiveness and facilitate processing units of operation such as buffer / media prep, virus inactivation etc."

"Today SciLog becomes a global business," said Juliette Schick, CEO and President of SciLog, "With this acquisition SciLog now has a platform in Parker to access global markets, distribution channels and resources to maximize SciLog's single-use product offerings and patent positions."

Parker's expanded capabilities in the biopharmaceutical market will be delivered globally through an extensive and growing global technical support network coupled with customer support centres in over 50 countries.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!